regdanvimab

Regdanvimab is a recombinant human IgG1 monoclonal antibody developed for the treatment of COVID-19. It specifically targets the receptor binding domain (RBD) of the spike protein of SARS-CoV-2, blocking its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. By preventing this interaction, regdanvimab neutralizes SARS-CoV-2 and inhibits viral entry and replication within human cells. The drug is administered as a single intravenous infusion, typically within seven days of symptom onset in patients at risk for severe disease progression. Regdanvimab has been approved in South Korea and authorized in the European Union for adults with COVID-19 who do not require supplemental oxygen but are at increased risk of developing severe disease[1][3][4][5].

Brand names

Regkirona

Other names

regdanvimab